Armata Pharmaceuticals, Inc.

$6.35

$-0.21 (-3.20%)

Jan 5, 2026

Price History (1Y)

Analysis

Armata Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector with approximately 60 employees. It has a market capitalization of $231.18M and annual revenues of $5.05M. The company's financial health is concerning, with operating margins reaching -670.9% and a profit margin of 0.0%. Additionally, it reported net income losses of -$46,901,000 in the last four quarters. The balance sheet indicates cash reserves of $14.76M but significant debt totaling $177.68M. Returns on equity (ROE) and assets (ROA) are not available for review. Armata Pharmaceuticals' valuation metrics are also noteworthy. With a price-to-sales ratio of 45.74, it is significantly valued compared to its peers. Furthermore, the company's forward P/E ratio stands at -4.04, indicating potential investors should carefully consider this metric in their analysis. The revenue growth rate has been negative at -61.0% year-over-year, and dividend yield is not applicable due to the absence of dividends.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.

Visit website →

Key Statistics

Market Cap
$231.18M
P/E Ratio
N/A
52-Week High
$16.34
52-Week Low
$0.90
Avg Volume
293.62K
Beta
1.31

Company Info

Exchange
ASE
Country
United States
Employees
60